Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-02-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司关于完成工商变更登记的公告.docx
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about the completion of a business registration change, specifically regarding the change in registered capital and updated business license information. It references a previous announcement about amendments to the company's articles of association but does not contain financial statements, management discussion, or detailed report content. The document is short (659 characters) and serves as a formal notification of a corporate registration update rather than a financial report or detailed governance document. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-02-09 Chinese
金宇生物技术股份有限公司关于2023年度非公开发行A股股票摊薄即期回报、填补回报措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 金宇生物技术股份有限公司 regarding the 2023 non-public issuance of A shares and its impact on immediate earnings dilution and compensation measures. It includes detailed financial assumptions, impact analysis on key financial indicators, risk warnings, necessity and rationality of the issuance, use of raised funds, company reserves in personnel, technology, and market, measures to address dilution, and commitments by the company and major shareholders to fulfill these measures. The document is regulatory in nature, focusing on disclosure related to capital raising and shareholder interests, but it is not a full financial report, earnings release, or management discussion. It is a formal announcement about a capital/financing update, specifically about a non-public share issuance and related dilution impact and mitigation. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8072 characters) and content confirm it is a substantive announcement, not merely a report publication or certification.
2023-02-07 Chinese
金宇生物技术股份有限公司独立董事关于公司第十一届董事会第五次会议相关事项的事前认可意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' pre-approval opinion regarding the company's non-public issuance of A shares in 2023. It references compliance with various laws and regulations, discusses the issuance plan, feasibility analysis, related party transactions, and management buyout aspects. The document is a formal opinion or approval statement related to a financing activity (non-public issuance of shares) rather than the actual issuance announcement or detailed financial report. It does not contain financial statements or earnings data but focuses on governance and regulatory compliance for the capital raising event. Given the content and context, this fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters and is a detailed opinion rather than a brief announcement, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2023-02-07 Chinese
金宇生物技术股份有限公司董事会关于公司管理层收购事宜致全体股东的报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a report from the board of directors to all shareholders regarding a management buyout (MBO) involving the company. It contains detailed information about the company, the parties involved in the buyout, shareholding structures before and after the transaction, conflict of interest disclosures, independent directors' opinions, and financial data relevant to the transaction. The document is comprehensive and focused on a corporate transaction involving management acquiring shares, which fits the definition of a Capital/Financing Update. It is not an annual report, audit report, or earnings release, nor is it a simple announcement or proxy solicitation. The length and detail confirm it is a full report on the management buyout transaction.
2023-02-07 Chinese
金宇生物技术股份有限公司关于非公开发行股票股东权益变动的提示性公告
Share Issue/Capital Change Classification · 100% confidence The document is a public announcement regarding a non-public issuance of shares by the company, detailing changes in shareholder equity and potential changes in control. It includes specifics about the share issuance plan, involved parties, shareholding percentages before and after issuance, and regulatory approvals required. The document is relatively short (1421 characters) and serves as a notification of a capital structure change due to a private placement of shares. It does not contain financial statements or detailed financial analysis but focuses on the capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2023-02-07 Chinese
金宇生物技术股份有限公司关于公司控股股东、实际控制人拟变更的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a proposed change in the company's actual controller due to a non-public share issuance. It discusses shareholding changes, control implications, and related agreements. It is not a full financial report, audit, or earnings release. It is not a simple notice of a report publication but a substantive announcement about control and shareholding changes. This fits the category of Capital/Financing Update (CAP), as it relates to financing activities and changes in capital structure affecting control.
2023-02-07 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.